Please provide your email address to receive an email when new articles are posted on . PCSK9 inhibitor prescriptions are rejected by insurers at a higher rate vs. other guideline-indicated ...
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a protein that binds to the LDL receptor on hepatocytes, promoting its internalization and degradation within the cell. [Repatha package insert ...
Add Yahoo as a preferred source to see more of our stories on Google. The FDA has approved LIB Therapeutics’ Lerochol (lerodalcibep-liga), a once-monthly, subcutaneously administered proprotein ...
MANNHEIM, Germany—Response to treatment is highly variable with the investigational PCSK9 inhibitor lerodalcibep (LIB Therapeutics), as well as with evolocumab (Repatha; Amgen), in patients who have ...
The PCSK9 inhibitor evolocumab (Repatha) got the FDA's blessing for cardiovascular protection, with or without a history of cardiovascular disease (CVD). Evolocumab is now indicated for the wider pool ...
Adding a PCSK9 inhibitor to maximally tolerated statins after a coronary or peripheral artery revascularization can help patients achieve LDL cholesterol goals better than standard care, data from the ...
Immune checkpoint therapy, particularly anti-PD-1/PD-L1 immunotherapy, have achieved significant results in the treatment of various tumors. However, most cancer patients show a low response rate to ...
A Mendelian randomization study reveals PCSK9 inhibitors may reduce low back pain (LBP) risk, while HMGCR and NPC1L1 ...
Over the past several days, two major developments have emerged in the world of cholesterol-lowering therapies—specifically concerning the heavy-hitters known as PCSK9 inhibitors. In this letter, I’d ...
"Clinically, there's heterogeneity among secondary-prevention patients," Dr Marc S Sabatine (Brigham and Women's Hospital, Boston, MA), who presented the former report on the three risk markers, told ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results